DM

SURPASS-2

🔴 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagonlike peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.

In patients with type 2 diabetes, tirzepatide was superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.

🔵 AMPLITUDE-O

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide (Exendin-based GLP-1 receptor agonist) at a dose of 4 or 6 mg than among those who received placebo.

🔵 Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial

In adults with overweight or obesity at high cardiovascular disease risk, once-daily liraglutide 3·0 mg plus lifestyle intervention significantly lowered visceral adipose tissue over 40 weeks of treatment. Visceral fat reduction may be one mechanism to explain the benefits seen on cardiovascular outcomes in previous trials with liraglutide among patients with type 2 diabetes.

🔴**Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials**

GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.